腫瘍性および野生型RAS- GTPの同時抑制ががん治療に用いられる
Matthew Holderfield1, Bianca J Lee1, Jingjing Jiang1
1Revolution Medicines, Redwood City, CA, USA.
Nature
|April 8, 2024
まとめ
新しい薬であるRMC-7977は,様々なRAS変異がんの治療に有望であることが示されています. KRAS,NRAS,HRASを含む複数のRAS変種を標的にし,治療が難しい腫瘍の可能性を提示します.
科学分野:
- 腫瘍学
- 分子生物学
- 薬物の発見
背景:
- RAS腫瘍遺伝子は (KRAS,NRAS,HRAS) がんでは頻繁に変異し,腫瘍の成長を促します.
- 現在のKRAS (G12C) 阻害剤は有効ですが,KRAS変異のサブセットのみに対応しています.
- 大半のRAS変異性がんを標的とした治療法については,著しく満たされていない需要がある.
研究 の 目的:
- 新しいRAS (ON) 多選択性阻害剤RMC-7977を導入する.
- RMC-7977の臨床前有効性を評価する.
- 既存の KRAS ((G12C)) 治療に耐性のあるモデルにおけるRMC-7977の活性を評価する.
主な方法:
- リバーシブルトライコンプレックスRAS阻害剤であるRMC-7977の開発
- 様々なRAS遺伝子型を持つ様々なRAS依存性がんモデルにおける臨床前試験
- KRAS ((G12C)) 阻害剤耐性モデルにおけるRMC-7977の評価
主要な成果:
- RMC-7977は,RAS依存性腫瘍,特にKRAS G12Xモデルに対して強力な活性を示した.
- 阻害剤は腫瘍の回帰を誘導し,臨床前モデルではよく耐えた.
- RMC-7977は,RAS経路のシグナリングをターゲットにすることで,KRAS (G12C) 耐性モデルの成長を効果的に抑制しました.
結論:
- RMC-7977のようなRASの多選択的阻害剤は,複数の腫瘍性および野生型のRAS同型を標的とすることができる.
- これらの阻害剤は,多くのRAS依存性がんを治療する可能性を秘めています.
- 関連する阻害剤であるRMC-6236は,KRAS変異の固体腫瘍に対する臨床試験中である.
関連する概念動画
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
Cancer-Critical Genes I: Proto-oncogenes
8.8K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.8K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


